Antibody blockade of Thy‐1 (CD90) impairs mouse cytotoxic T lymphocyte induction by anti‐CD3 monoclonal antibody

Haeryfar, S. M. Mansour; Conrad, David M.; Musgrave, Bruce L.

doi:10.1111/j.1440-1711.2005.01342.x

Cited by 15 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibition of T cell activation through down-regulation of TCR-CD3 expression can be mediated by an anti-CD90 antibody [ [19] ] . Furthermore, Thy-1 signaling promotes the in vitro generation of CTLs that kill target cells in a granule-dependent fashion [ [20] ] . To examine whether or not this age-associated change of CD90 expression contributes to the decreased T cell response with aging, we compared the responses of CD90 hi and CD90 low CD8 T cells of aged Tg mice.…”

Section: Resultsmentioning

confidence: 99%

Impaired specific CD8 T cell response with aging is not due to decreased expression of CD90 on TCR transgenic T cells

2013

View full text Add to dashboard Cite

BackgroundCD90 (Thy-1) is a small glycoprotein that is particularly abundant on the surface of mouse thymocytes and peripheral T cells, and is often used as a marker in adoptive transfer experiments to distinguish donor and recipient T cells with different CD90 subtypes. We have performed adoptive transfer experiments with T cell receptor transgenic (TCR Tg) mice to study the impaired CD8 T cell response with aging.FindingsAfter stimulation with a CD8 T cell epitope, HA518-524, the response of TCR Tg CD8 T cells from aged mice was decreased compared to the response of TCR Tg T cells from young mice. CD90 expression was also substantially decreased on the TCR Tg CD8 T cells of aged mice. However, the responses of CD90hi and CD90low CD8 T cells of the aged mice were similar in both early activation and proliferation, demonstrating that the impaired Tg T cell response with aging is not associated with the altered CD90 expression on CD8 T cells.ConclusionsThe impaired Tg CD8 T cell response in aged mice is not due to age-associated changes in CD90 expression on Tg CD8 T cells.

show abstract

Section: Resultsmentioning

confidence: 99%

Impaired specific CD8 T cell response with aging is not due to decreased expression of CD90 on TCR transgenic T cells

2013

View full text Add to dashboard Cite

show abstract

“…CD90 is a glycosyl phosphatidylinositol-anchored membrane glycoprotein of the immunoglobulin superfamily expressed mainly on the surface of leukocytes. 65 This marker is involved in cell-cell and cell-adhesive matrix interactions. Yang et al found that the CD90-positive subpopulation showed a distinct higher tumorigenicity and metastatic potential in a mouse xenograft model when compared with CD90-negative counterparts.…”

Section: Cd90mentioning

confidence: 99%

Targeting cancer stem cells by using the nanoparticles

Hong

Jang

Lee

et al. 2015

IJN

View full text Add to dashboard Cite

Cancer stem cells (CSCs) have been shown to be markedly resistant to conventional cancer treatments such as chemotherapy and radiation therapy. Therefore, therapeutic strategies that selectively target CSCs will ultimately lead to better cancer treatments. Currently, accessible conventional therapeutic agents mainly eliminate the bulk tumor but do not eliminate CSCs. Therefore, the discovery and improvement of CSC-targeting therapeutic agents are necessary. Nanoparticles effectively inhibit multiple types of CSCs by targeting specific signaling pathways (Wnt/β-catenin, Notch, transforming growth factor-β, and hedgehog signaling) and/or specific markers (aldehyde dehydrogenases, CD44, CD90, and CD133) critically involved in CSC function and maintenance. In this review article, we summarized a number of findings to provide current information about their therapeutic potential of nanoparticles in various cancer cell types and CSCs.

show abstract

“…In contrast, the majority of studies using anti-CD90 Abs demonstrated a mitogenic role for CD90 in T cell activation [22,25,31,33]. One anti-Thy-1 Ab, clone G7, augmented TCR/CD28-driven T cell proliferation [33]. Another anti-CD90 Ab, 30-H12, had no potential to activate T cells, but, was able to block CD90 signaling as a soluble form, resulting in inhibition of the anti-CD3-induced proliferation of CD4 T cells [33], suggesting an important co-stimulatory role for CD90 signaling in mouse T cell activation.…”

Section: Discussionmentioning

confidence: 79%

“…These reports suggest that CD90 functions as a negative regulator of TCR-mediated signaling. In contrast, the majority of studies using anti-CD90 Abs demonstrated a mitogenic role for CD90 in T cell activation [22,25,31,33]. One anti-Thy-1 Ab, clone G7, augmented TCR/CD28-driven T cell proliferation [33].…”

Section: Discussionmentioning

confidence: 93%

“…One anti-Thy-1 Ab, clone G7, augmented TCR/CD28-driven T cell proliferation [33]. Another anti-CD90 Ab, 30-H12, had no potential to activate T cells, but, was able to block CD90 signaling as a soluble form, resulting in inhibition of the anti-CD3-induced proliferation of CD4 T cells [33], suggesting an important co-stimulatory role for CD90 signaling in mouse T cell activation. In this paper, we reported a new anti-CD90 Ab, LP5, which was established based on its suppressive activity against CD4 T cell activation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of T cell activation through down-regulation of TCR-CD3 expression mediated by an anti-CD90 Ab

et al. 2011

View full text Add to dashboard Cite

We are trying to develop new Abs that can manipulate CD4 T cell responses and are usable as immunosuppressive agents. To this end, we performed functional screening, in which we examined the effect of an Ab on the proliferation of mouse CD4 T cells upon activation. The Ab, LP5, inhibited the activation of CD4 T cells stimulated with an anti-CD3 Ab or peptide antigen. The Ab alone had no stimulatory effect on CD4 T cells. Biochemical experiments demonstrated that LP5 recognized the Thy-1 (CD90) molecule. Interestingly, the treatment of CD4 T cells with LP5 in vitro induced a temporary down-regulation of CD3 expression at the cell surface. TCR molecules were also affected. Other anti-CD90 Abs not inhibitory to CD4 T cell activation failed to induce a reduction in CD3. Experiments in vitro revealed that the down-regulation caused by LP5 is due to an accelerated endocytosis of cell surface CD3. In addition, it was shown that CD3 down-regulation before or in the early stages of T cell activation is critical for the induction of hyporesponsiveness. Experiments in vivo showed that pre-treatment of CD4 T cells with LP5 inhibited the rejection of semi-allogeneic bone marrow transplants. Based on these observations, we propose that CD3 down-regulation without any stimulatory activity against T cells could be one approach to inhibiting T cell activation, and CD90 would be an appropriate target.

show abstract

Antibody blockade of Thy‐1 (CD90) impairs mouse cytotoxic T lymphocyte induction by anti‐CD3 monoclonal antibody

Cited by 15 publications

References 41 publications

Impaired specific CD8 T cell response with aging is not due to decreased expression of CD90 on TCR transgenic T cells

Impaired specific CD8 T cell response with aging is not due to decreased expression of CD90 on TCR transgenic T cells

Targeting cancer stem cells by using the nanoparticles

Inhibition of T cell activation through down-regulation of TCR-CD3 expression mediated by an anti-CD90 Ab

Contact Info

Product

Resources

About